HGH 191AA kalkulator

What Is HGH 191aa?

HGH 191aa is recombinant human growth hormone (rhGH) consisting of exactly 191 amino acids. The "191aa" designation refers precisely to this chain length and distinguishes the molecularly identical form from older or incomplete 192-amino-acid sequences that carry an additional methionine residue. The 191-amino-acid form matches, residue for residue, the endogenous somatropin produced by the somatotroph cells of the anterior pituitary gland. Because of this structural identity, HGH 191aa is treated in research as the reference form of growth hormone rather than as an analog derivative.

HGH 191aa is manufactured biotechnologically through recombinant DNA expression, typically in Escherichia coli or mammalian cell systems. The molecule has a molar mass of approximately 22,124 g/mol and the empirical formula C₉₉₀H₁₅₂₉N₂₆₃O₂₉₉S₇. In its freeze-dried form it is a white, compact powder that must be reconstituted before use. Unlike secretagogues such as sermorelin, CJC-1295, or ipamorelin — which prompt the body to produce its own growth hormone — HGH 191aa is the finished hormone itself. It therefore acts directly at the growth hormone receptor without requiring pituitary involvement.

In scientific research, HGH 191aa is used to study the somatotropic axis, JAK2/STAT5 signal transduction, and the downstream induction of insulin-like growth factor 1 (IGF-1). Preclinical models examine protein metabolism, lipolysis, bone and connective tissue remodeling, and the regulation of glucose metabolism, among other endpoints. HGH 191aa is intended strictly for research purposes and is not an approved drug outside of tightly regulated medical indications.

Mechanisms of Action

HGH 191aa exerts its biological effects by binding to the growth hormone receptor, a member of the cytokine receptor superfamily. A single hormone molecule binds two receptor units, triggers their dimerization, and thereby initiates a cascade of intracellular signaling pathways. Several distinct biological effects follow from this:

• Growth hormone receptor activation: Receptor dimerization activates the receptor-associated Janus kinase 2 (JAK2), which in turn phosphorylates STAT5. STAT5 translocates to the cell nucleus and regulates the transcription of growth-dependent genes. This pathway is the central mediator of nearly all the anabolic effects of growth hormone.
• IGF-1 induction: A large share of the anabolic effect is indirect, mediated through IGF-1. Growth hormone stimulates IGF-1 synthesis, primarily in the liver. IGF-1 is a potent mediator of cell division, protein synthesis, and tissue growth, and has a substantially longer half-life than growth hormone itself.
• Lipolysis: Growth hormone promotes the mobilization of fatty acids from adipose tissue by activating hormone-sensitive lipase and inhibiting lipoprotein lipase. In preclinical models this shifts substrate metabolism toward fat oxidation, particularly in the visceral fat depot.
• Protein synthesis and nitrogen retention: Growth hormone increases cellular amino acid uptake and promotes protein synthesis in muscle and connective tissue. A positive nitrogen balance is observed alongside this — a classic marker of an anabolic metabolic state.
• Effects on glucose metabolism: Growth hormone has a counter-regulatory, insulin-antagonistic component. It can reduce peripheral glucose uptake and promote gluconeogenesis, which is why glucose homeostasis is monitored closely in research protocols.

Dosage Calculation

HGH 191aa is one of the few compounds expressed in both milligrams (mg) and International Units (IU). This dual unit is the most common source of dosing errors, so the relationship between the two deserves a careful look.

Standard Dosing Parameters

• mg-to-IU conversion: As a rule of thumb, roughly 3 IU per 1 mg of recombinant somatropin. A 10 IU vial therefore corresponds to approximately 3.33 mg of active substance. The exact factor can vary slightly between batches and manufacturers and is stated on the certificate of analysis.
• Conservative range: 1 IU per administration
• Standard range: 2 IU per administration (the most common starting point in research protocols)
• Higher range: up to 4–5 IU per administration
• Frequency: once daily, typically subcutaneous
• Recommended syringe: 0.3 mL insulin syringe (U100, 29–31 gauge)

Example Calculation: 10 IU Vial with 1 mL BAC Water

The most common vial size is 10 IU. Reconstituting the vial with 1 mL of bacteriostatic water gives a concentration of 10 IU/mL. On a U100 insulin syringe, 100 units equal exactly 1 mL, so the entire vial is spread across 100 syringe units.

• 1 IU dose: 1 ÷ 10 = 0.10 mL (10 units on a U100 syringe)
• 2 IU dose: 2 ÷ 10 = 0.20 mL (20 units)
• 4 IU dose: 4 ÷ 10 = 0.40 mL (40 units)
• 5 IU dose: 5 ÷ 10 = 0.50 mL (50 units)

At a daily dose of 2 IU, a 10 IU vial lasts roughly 5 days. Working with a larger reconstitution volume — say 2 mL instead of 1 mL — halves the concentration to 5 IU/mL and requires drawing twice the syringe volume for the same IU dose. This is exactly where the calculator helps: use the HGH 191aa calculator above to determine the exact syringe volume for any vial size, BAC water volume, and target dose in IU.

Reconstitution

HGH 191aa is supplied as a lyophilized (freeze-dried) powder in sealed vials and must be reconstituted with bacteriostatic water (BAC water) before use. BAC water contains 0.9% benzyl alcohol, which inhibits microbial growth and significantly extends the usable window of the reconstituted solution. Sterile water for injection is only suitable for single use and should be avoided for multi-dose vials. Growth hormone is a relatively large, fragile protein, so gentle handling is essential.

Step-by-Step Reconstitution Protocol

1. Gather supplies: the HGH 191aa vial, a bacteriostatic water vial, alcohol swabs, a sterile draw needle (18–21 gauge), and the U100 insulin syringe for administration.
2. Wipe the rubber septa of both vials with fresh alcohol swabs and allow them to air-dry for about 30 seconds. Do not touch or blow on the septa afterward.
3. Draw the desired volume of BAC water — 1 mL is standard for a 10 IU vial. The volume you choose directly determines the resulting concentration in IU/mL.
4. Insert the needle into the peptide vial at an angle, directing the tip toward the inner glass wall rather than the powder cake. A direct jet onto the lyophilized cake can mechanically damage the fragile protein molecule.
5. Slowly push the plunger so that the BAC water runs down the inner glass wall and wets the powder from below.
6. Gently roll the vial between your palms or swirl it softly until the powder has fully dissolved. Never shake or vortex, as shear forces and foaming can denature growth hormone. The solution should appear clear and colorless when finished.
7. Label the vial with the reconstitution date and concentration, for example "HGH 191aa 10 IU/mL, reconstituted [date]".

If the solution appears cloudy, discolored, or contains visible particulate matter, discard the vial and do not use it.

Storage and Shelf Life

• Lyophilized powder (unreconstituted): Store at −20°C for long-term storage; in this form HGH 191aa is stable for many months. Short-term storage at 2–8°C in a refrigerator is acceptable. Protect from light and moisture, and do not leave at room temperature for extended periods.
• Reconstituted solution: Always store in the refrigerator at 2–8°C. Reconstituted growth hormone is considerably more fragile than the powder and should be used within approximately 2–3 weeks. Keep the vial upright and away from light.
• Do not refreeze. Freeze-thaw cycles cause protein aggregation and a measurable loss of activity. Once reconstituted, the vial must remain refrigerated throughout.
• Protect from heat and agitation: Temperatures above 25°C, direct sunlight, and vigorous shaking accelerate degradation. For longer transport, use an insulated cooler with an ice pack; commercial medication pouches maintain 2–8°C for 24–48 hours.

Side Effects and Safety Profile

HGH 191aa is the complete growth hormone and therefore a biologically highly active substance. Unlike many smaller research peptides, it intervenes directly and forcefully in endocrine regulation. Observations in the research literature show a clearly dose-dependent response pattern. Because use outside of well-defined medical indications remains within the research domain, careful risk assessment is essential.

Commonly Reported Observations

• Water retention and edema, often first visible in the hands and ankles. This effect is typically dose-dependent and recedes when the dose is reduced.
• Joint and muscle pain (arthralgia), along with a feeling of tightness or stiffness, particularly at the start of a protocol or at higher doses.
• Carpal-tunnel-like symptoms with tingling or numbness in the fingers, usually a consequence of fluid accumulation in the tissue.
• Transient mild redness, swelling, or discomfort at the injection site, which can be minimized by rotating injection sites.

Less Common or Theoretical Concerns

• Impaired glucose tolerance: Growth hormone is insulin-antagonistic and can reduce insulin sensitivity. Elevated blood glucose is a known potential consequence, particularly at high doses or with prolonged use.
• Excessive tissue proliferation: Through IGF-1, growth hormone promotes cell division and tissue growth. With chronically elevated levels, the literature discusses concerns about acromegaly-like changes and the theoretical promotion of pre-existing proliferative processes.
• Suppression of endogenous production: Administered growth hormone can dampen pituitary self-secretion via negative feedback. The endocrine axis is therefore subject to careful monitoring in research protocols.
• Effects on the thyroid axis: Growth hormone can alter the conversion of T4 to T3, which is why thyroid parameters are monitored in longer protocols.

Contraindications

• Active cancer or history of malignancy (without oncological supervision)
• Diabetes mellitus or any existing disorder of glucose metabolism
• Pregnancy and breastfeeding (insufficient safety data)
• Known hypersensitivity to any component of the preparation

Growth hormone is a potent endocrine-active substance whose effects extend across the entire organism. Consultation with a qualified physician before any use is strongly recommended.

Combinations and Stacks

HGH 191aa and the GH Axis

HGH 191aa sits at the center of the somatotropic axis, which is why research often examines it alongside substances that target other levers of the same axis. The conceptual distinction is important: HGH 191aa is the finished hormone, whereas peptides such as tesamorelin act as secretagogues that stimulate the body's own release. Anyone comparing or combining the two approaches should keep the different mechanisms clearly separate.

Tesamorelin is a stabilized GHRH analog that prompts the pituitary to release growth hormone in its own pulsatile pattern rather than supplying it directly. In research, tesamorelin is often described as a more physiological approach to the GH axis because the natural pulsatile rhythm is preserved. Detailed dosing guidance is available in the tesamorelin calculator.

HGH 191aa and Tissue Repair Peptides

For research questions around tissue repair, HGH 191aa is frequently examined alongside BPC-157 and TB-500. There is a noteworthy synergistic relationship here: BPC-157 upregulates the expression of growth hormone receptors in tissue, sensitizing it to circulating growth hormone. While HGH 191aa and IGF-1 shape the systemic anabolic environment, BPC-157 and TB-500 address local repair pathways such as angiogenesis, collagen synthesis, and cell migration.

HGH 191aa as a Standalone

In many research protocols, HGH 191aa is first studied as a single agent in order to cleanly separate its dose-dependent effects on IGF-1, lipolysis, and protein metabolism from other influences. Because growth hormone intervenes forcefully in metabolism, isolated study is often the methodologically clean choice.

Research-grade HGH 191aa is available directly from BergdorfBio: HGH 191aa at BergdorfBio.

Frequently Asked Questions

What does the "191aa" designation mean?

"191aa" stands for 191 amino acids — the exact residue count of the complete growth hormone chain. This variant is molecularly identical to endogenous somatropin. The older 192-amino-acid form carries an additional N-terminal methionine and is considered less true to nature. The 191aa label therefore signals the sequence-identical standard form of growth hormone.

How do I convert mg to IU?

As a rule of thumb, roughly 3 IU per 1 mg of recombinant somatropin. A 10 IU vial therefore corresponds to approximately 3.33 mg. The exact factor can vary slightly between batches and manufacturers and is documented on the certificate of analysis. In day-to-day research, growth hormone is most often dosed in IU because that unit was historically tied to biological activity.

How does HGH 191aa differ from tesamorelin or sermorelin?

HGH 191aa is the finished growth hormone and acts directly at the growth hormone receptor. Tesamorelin and sermorelin, by contrast, are secretagogues: they prompt the pituitary to release endogenous growth hormone. Secretagogues preserve the natural pulsatile rhythm and feedback loops, whereas directly supplied hormone produces a more constant, non-pulsatile profile.

Why does HGH 191aa have such a short half-life?

The plasma half-life of recombinant growth hormone is around 20 minutes. The hormone is cleared rapidly by the liver and kidneys. Despite this short residence time in plasma, the biological effects last considerably longer because they are largely mediated indirectly through the longer-lived IGF-1, whose half-life is on the order of several hours.

Why must reconstituted HGH 191aa not be shaken?

Growth hormone is a comparatively large and fragile protein. Vigorous shaking generates shear forces and foam, which can cause the protein molecules to unfold and aggregate. Aggregated hormone loses biological activity. The vial should therefore only be gently rolled between the palms or swirled softly.

Is HGH 191aa detectable in sports drug testing?

Growth hormone is on the WADA prohibited list and is banned in sport at all times. Specialized detection methods exist, including the isoform test and the biomarker-based approach using IGF-1 and P-III-NP. Athletes subject to WADA-compliant testing must treat growth hormone unequivocally as a prohibited substance and verify the applicable anti-doping rules in advance.

How should HGH 191aa be stored after reconstitution?

Reconstituted HGH 191aa belongs in the refrigerator at 2–8°C throughout and should be used within approximately 2–3 weeks. Store the vial upright, protected from light, and never refreeze it. The unreconstituted powder is considerably more robust and can be stored at −20°C for many months.

Where can I buy HGH 191aa?

BergdorfBio offers HGH 191aa in research grade with verified purity and concentration. View the product page: buy HGH 191aa at BergdorfBio. All products are sold strictly for research purposes.

Medical Disclaimer: The information on this page is provided for educational and research purposes only. HGH 191aa is not an approved drug or medical treatment and is sold strictly for research use. Nothing on this page constitutes medical advice, diagnosis, or a recommendation to use any specific compound. Always consult a qualified healthcare professional before beginning any peptide protocol. BergdorfBio assumes no liability for the use or misuse of the information presented here.